3110062M04Rik Activators
3110062M04Rik Activators are a collection of chemical compounds that enhance the functional activity of 3110062M04Rik by modulating specific signaling pathways and cellular processes to which 3110062M04Rik is responsive. The activation of adenylate cyclase by compounds such as Forskolin leads to an increase in intracellular cAMP levels, which in turn activates PKA. This kinase is crucial for several cellular processes and could enhance the activity of 3110062M04Rik if its function is cAMP-dependent. Protein Kinase A Activators are a select group of chemical compounds that enhance the functional activity of Protein Kinase A through various signaling pathways, primarily by increasing the levels of cAMP or mimicking its action. Forskolin directly stimulates adenylate cyclase, thereby raising intracellular cAMP levels and subsequently activating Protein Kinase A, which leads to enhanced phosphorylation of downstream targets. Compounds like IBMX, Dipyridamole,
Anagrelide, and Vinpocetine indirectly enhance Protein Kinase A activity through their inhibition of various phosphodiesterases, preventing the degradation of cAMP and sustaining the activation of Protein Kinase A. cAMP analogs such as Sp-cAMPS and 8-CPT-cAMP specifically activate Protein Kinase A by binding to its regulatory subunits, thus mimicking the natural activator cAMP and enhancing Protein Kinase A's catalytic efficiency. Additionally, certain compounds like H-89, at specific concentrations, can have an allosteric effect on Protein Kinase A, leading to its enhanced activity. Rolipram and Milrinone, by selectively inhibiting phosphodiesterase 4 and phosphodiesterase III respectively, ensure an increase in cAMP concentrations, which in turn specifically promotes Protein Kinase A activation. Cilostamide and Etazolate also contribute to the enhancement of Protein Kinase A activity by increasing cAMP levels through their inhibition of specific phosphodiesterases.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP, leading to their accumulation. This elevation can enhance 3110062M04Rik activity by sustaining the signaling pathways where these cyclic nucleotides act as secondary messengers. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a tyrosine kinase inhibitor that can diminish competitive signaling pathways, potentially allowing 3110062M04Rik more functional prominence in cellular processes that are regulated by tyrosine kinase activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium levels, which can activate calcium-dependent proteins and pathways that may indirectly enhance the activity of 3110062M04Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate various substrates and may enhance 3110062M04Rik activity through PKC-dependent signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, altering downstream signaling pathways, such as Akt, which can indirectly enhance 3110062M04Rik activity by modulating processes where PI3K/Akt signaling is involved. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate acts through its receptors to initiate signaling pathways that can lead to the activation of proteins downstream, potentially enhancing the function of 3110062M04Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels, which may indirectly enhance the activity of 3110062M04Rik through calcium-dependent signaling. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB203580 is a p38 MAPK inhibitor, which might lead to the enhancement of 3110062M04Rik activity by influencing cellular responses where p38 MAPK plays an inhibitory role. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a divalent cation ionophore, particularly for calcium, which can increase intracellular calcium levels and enhance the activity of 3110062M04Rik through calcium-dependent signaling mechanisms. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that could selectively enhance 3110062M04Rik activity by inhibiting kinases that otherwise suppress its function. | ||||||